Open access • Posted Content • DOI:10.1101/2020.04.14.040204

Relevance of enriched expression of SARS-CoV-2 binding receptor ACE2 in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients — Source link

Ashutosh Kumar, Muneeb A. Faiq, Vikas Pareek, Khursheed Raza ...+10 more authors

Institutions: All India Institute of Medical Sciences, New York University, National Brain Research Centre, University of Pittsburgh ...+7 more institutions

Published on: 15 Apr 2020 - bioRxiv (Cold Spring Harbor Laboratory)

Topics: Intestinal epithelium, Pancreas, Epithelium, SLC5A1 and Stomach

Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients

Short title: Relevance of ACE2 and TMPRSS2 gastrointestinal expressions in COVID-19 pathogenesis

*Ashutosh Kumar[1,2], Muneeb A. Faiq[1,3], Vikas Pareek[1,4], Khursheed Raza[1,5], Ravi K. Narayan[1,2], Pranav Prasoon[1,6], Pavan Kumar[1,7], Maheswari Kulandhasamy[1,8], Chiman Kumari[1,9], Kamla Kant[1,10], Himanshu N. Singh[1,11], Rizwana Qadri[1,12], Sada N. Pandey[1,13], Santosh Kumar[1,14]

1- Etiologically Elusive Disorders Research Network (EEDRN), New Delhi, India
2- Department of Anatomy, All India Institute of Medical Sciences (AIIMS), Patna, India
3- New York University (NYU) Langone Health Center, NYU Robert I Grossman School of Medicine, New York, New York, USA
4- National Brain Research Center, Manesar, Haryana, India
5- Department of Anatomy, All India Institute of Medical Sciences, Deoghar, India
6- Pittsburgh Center for Pain Research, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
7- Department of Pediatrics, Medical University of South Carolina, Charleston, USA
8- Department of Biochemistry, Maulana Azad Medical College (MAMC), New Delhi, India
9- Department of Anatomy, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
10- Department of Microbiology, All India Institute of Medical Sciences (AIIMS), Bathinda, India
11- TAGC-INSERM, U1090, Aix Marseille University, Marseille, France
12- Neuro-oncology Laboratory, Rockefeller University, New York, New York, USA
13- Department of Zoology, Banaras Hindu University (BHU), Varanasi, India
14- Department of Anesthesiology and Critical Care Medicine, School of Medicine, Johns Hopkins University, Baltimore, USA

*Corresponding author
Ashutosh Kumar
drashutoshkumar at aiimspatna.org

Abstract

Introduction

COVID-19 is caused by a new strain of coronavirus called SARS-coronavirus-2 (SARS-CoV-2), which is a positive sense single strand RNA virus. In humans, it binds to angiotensin converting enzyme 2 (ACE2) with the help a structural protein on its surface called the S-spike. Further, cleavage of the viral spike protein (S) by the proteases like transmembrane serine protease 2 (TMPRSS2) or Cathepsin L (CTSL) is essential to effectuate host cell membrane fusion and virus infectivity. COVID-19 poses intriguing issues with imperative relevance to clinicians. The pathogenesis of GI symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 are of particular relevance because they cannot be sufficiently explained from the existing knowledge of the viral diseases. Tissue specific variations of SARS-CoV-2 cell entry related receptors expression in healthy individuals can help in understanding the pathophysiological basis the aforementioned collection of symptoms.

Materials and Methods

The data were downloaded from the Human Protein Atlas available at (https://www.proteinatlas.org/humanproteome/sars-cov-2) and the tissue specific expressions (both mRNA and protein) of ACE2 and TMPRSS2 as yielded from the studies with RNA sequencing and immunohistochemistry (IHC) were analyzed as a function of the various components of the digestive tract. A digestive system specific functional enrichment map of ACE2 gene was created using g:profiler (https://biit.cs.ut.ee/gprofiler/gost) utility and the data were visualized using Cytoscape software, version 3.7.2 (https://cytoscape.org/).

Results

The correlated expression (transcriptomic and proteomic) of ACE2 (to which SARS-CoV-2 binds through the S-spike) was found to be enriched in the lower gastrointestinal tract (GIT) (highest in small intestine, followed by colon and rectum), and was undetectable in the upper GIT components: mouth cavity (tongue, oral mucosa, and salivary glands), esophagus, and stomach. High expression of ACE2 was noted in the glandular cells as well as in the enterocytes in the lining epithelium (including brush border epithelium). Among other digestive system organs, Gall bladder (GB) showed high expression of ACE2 in glandular cells, while any protein expression was undetectable in liver and pancreas. TMPRSS2 was found enhanced in GIT and exocrine glands of pancreas, and co-localized with ACE2 in enterocytes.

Conclusions

Based on the findings of this study and supportive evidence from the literature we propose that a SARS-CoV-2 binding with ACE2 mediates dysregulation of the sodium dependent nutrient transporters and hence may be a plausible basis for the digestive symptoms in COVID-19 patients. ACE2 mediated dysregulation of sodium dependent glucose transporter (SGLT1 or SLC5A1) in the intestinal epithelium also links it to the pathogenesis of diabetes mellitus which can be a possible reason for the associated mortality in COVID-19 patients with diabetes. High expression of ACE2 in mucosal cells of the intestine and GB make these organs potential sites for the virus entry and replication. Continued replication of the virus at

these ACE2 enriched sites may be a basis for the disease recurrence reported in some, thought to be cured, patients.

Keywords: SARS-CoV2, digestive symptoms, recurrence, amino acid transporter, glucose transporter

Graphical Abstract



Introduction

The world is currently reeling in an alarming outbreak of novel coronavirus disease 2019 referred to as COVID-19. COVID-19 is caused by a new coronavirus strain severe acute respiratory syndrome coronavirus 2 (SARS CoV-2)—a positive sense single strand RNA virus. Recent studies which decoded structure of the virus showed binding of its S-spike protein to a human protein- angiotensin converting enzyme 2 (ACE2) (1-3). Following ACE2 binding, cleavage of the viral spike protein (S) by the serine proteases like transmembrane serine protease 2 (TMPRSS2) or Cathepsin L (CTSL) is essential to effectuate host cell membrane fusion and virus infectivity (4). Clinical presentation in COVID-19 patients is highly diverse and majority of them primarily presents with pulmonary symptoms (cough, fever, shortness of breath) (5). In addition, some of the patients present with digestive symptoms like diarrhea, nausea, vomiting and abdominal pain (data ranges from 3.8% to 50.5%) (6). Digestive symptoms have been the only presentations in some of the patients (8,9). Digestive symptoms are not unique to the COVID-19 and usually present in the gastroenteritis caused by many other respiratory syndrome viruses like SARS-CoV-1 and influenza A and B (10,11). However, how SARS-CoV-2 makes entry into the gastrointestinal (GI) tissue leading to gastroenteritis-like features, does not imbibe sufficient and coherent explanation in the light of the existing literature. Some investigators have speculated a fecal-oral route of transmission based on fecal shedding of viral proteins and infectious virus in some COVID-19 patients (12,13).

Knowing the expression pattern of ACE2 and one of the proteases, TMPRSS2 in gastrointestinal tract (GIT) may explicate the pathogenesis of digestive symptoms in COVID-19. Digestive juices and enzymes secreted from the liver, gall bladder (GB) and pancreas play an important role in maintenance of the secretions and absorption of nutrients across intestinal epithelium. Hence their possible dysfunction in COVID-19 patients needs to be examined in order to understand pathogenesis of the digestive symptoms which, in turn, prevent some COVID-19 associated mortality.

Existing literature on the role of ACE2 in regulation of the ion transporters which maintain secretion/absorption across intestinal epithelium provide a clue that digestive symptoms in COVID-19 may have an ACE2 based etiogenesis (11,14-16). Investigating the ACE2 expression pattern of digestive system components may also help to explain exacerbated diabetic complications and mortality in COVID-19 patients. Diabetes has been noted as a co-morbidity (16.2%) in COVID-19 and has contributed to increased mortality (22%) (17) Existing literature implicates ACE2 mediated dysregulation of sodium dependent glucose transporter (SGLT1 or SLC5A1) at intestinal epithelium in the pathogenesis of the diabetes mellitus (18,19).

In this study, we aim at examining the plausibility (based on the tissue specific expression of ACE2) whether any of the digestive system components can be involved in the continued replication of the SARS-CoV-2 after pulmonary symptoms are relieved. Many incidences of disease recurrence have been reported in COVID-19 patients even after being discharged from the hospital. Studies have reported continued shedding of SARS-CoV-2 in the feces of COVID-19 patients up to five weeks after disappearance of the pulmonary symptoms bolstering the indication that a residual persisting of virus inside the digestive system components may be a reason for the disease recurrence (20).

We aimed to validate transcriptomic and proteomic expression of ACE2 and TMPRSS2 in the components of human digestive system (including liver, GB, and pancreas) in tissues

derived from the healthy individuals to understand pathophysiological basis of the digestive symptoms in COVID-19 patients.

Materials and Methods

We analyzed the tissue specific distribution of ACE2 and TMPRSS2 (mRNA and protein) in digestive system components (GIT, liver & GB, and pancreas) using RNA sequencing and immunohistochemistry (IHC) data available in Human Protein Atlas (https://www.proteinatlas.org/humanproteome/sars-cov-2). A digestive system specific functional enrichment map of ACE2 gene was constructed using g:profiler (https://biit.cs.ut.ee/gprofiler/gost) utility and viewed with Cytoscape software, version 3.7.2 (https://cytoscape.org/). Since no direct subject or patient data were used in this study, clearance from the Institutional Ethics Committee was precluded.

Human Protein Atlas methods

Estimation of mRNA expression and localization of human proteins were performed by the source laboratory using deep sequencing of RNA (RNA-seq) and IHC in normal tissue.

IHC

As described by the source labs, specimens containing normal tissue were collected and sampled from anonymized paraffin embedded material of surgical specimens, in accordance with approval from the local ethics committee. The specimens were derived from surgical material, normal was defined by morphological parameters and absence of neoplasia. IHC staining was performed using a standard protocol on normal tissue microarray (https://www.proteinatlas.org/download/IHC_protocol.pdf). Antibodies against human ACE2 (HPA000288, CAB026174) and TMPRSS2 (HPA035787) were labeled with DAB (3, 3'-diaminobenzidine) stain. Protein expression score was done based on the staining intensity (negative, weak, moderate or strong) and fraction of stained cells (<25%, 25-75% or >75%). For each protein, the IHC staining profile was matched with mRNA expression data and gene/protein characterization data to yield an 'annotated protein expression' profile.

Transcriptomics

The Human Protein Atlas collects transcriptomic data from the three databases (HPA, GTEx and FANTOM5). HPA RNAseq was performed on human tissue samples from healthy individuals (Accession no: PRJEB4337, Ensembl: ENSG00000130234 (version 92.38). Total RNA was extracted from the tissue samples using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The extracted RNA samples were analyzed using either an Experion automated electrophoresis system (Bio-Rad Laboratories, Hercules, CA, USA) with the standard-sensitivity RNA chip or an Agilent 2100 Bioanalyzer system (Agilent Biotechnologies, Palo Alto, USA) with the RNA 6000 Nano Labchip Kit. Only samples of high-quality RNA (RNA Integrity Number 7.5) were used for the mRNA sample preparation for sequencing. mRNA sequencing was performed on Illumina HiSeq2000 and 2500 machines (Illumina, San Diego, CA, USA) using the standard Illumina RNA-seq protocol with a read length of 2x100 bases. Transcript abundance estimation was performed using Kallisto v0.43.1 (https://pachterlab.github.io/kallisto/about). The normalized Tags Per Million (TPM) for each gene from the three databases were calculated and included in the Human Protein Atlas. Each tissue was categorized for the intensity of gene expression using a cutoff value of 1 NX as a limit for detection across all tissues. A tissue was categorized (i) enriched if it had NX level at least four times higher than other tissues, (ii) low specificity if NX $\geq$ 1 in at least one tissue, (iii) Not detected if NX < 1 in all tissues. Further

details of the assays and annotation used by the Human Protein Atlas can be accessed at: https://www.proteinatlas.org/about/assays+annotation#ihk.

Gene enrichment analysis and visualization

Functional enrichment analysis of the ACE2 gene was performed with g: profiler web server (https://biit.cs.ut.ee/gprofiler/gost) and p-value computed using a Fisher's exact test with multiple-test correction. Enrichment map visualization was done with the help of Cytoscape software, version 3.7.2 (https://cytoscape.org/).

Results (Fig. 1-3, S1-3, Table 1, S1-2)

The transcriptomic and proteomic expression of ACE2 displayed high enrichment in the lower GIT (small intestine, colon, and rectum) (Fig. 1, 2e-h, Table 1). It was highest in the parts of small intestine followed by the colon and the rectum, and nearly absent (negligible/low mRNA expression and undetectable protein expression) in the upper GIT components: mouth cavity (including tongue, oral mucosa, and salivary glands), esophagus, and stomach (Fig. 1, 2a-d). GB showed high glandular expression of ACE2, while any protein expression was undetectable in appendix, liver (hepatocytes and bile duct), and pancreas (exocrine and endocrine glandular tissue) (though minimal mRNA expression was noted) (Fig. 3). Intense ACE2 expression was noted in the glandular cells as well as in the enterocytes in the lining epithelium of the lower GIT (Fig. 2e-h). The cellular expression of ACE2 was visible in the enterocyte cytoplasm and in the apical brush border (Fig. 2e-h, marked with arrow heads). The digestive system specific functional enrichment map for ACE2 gene were related to digestive functions like enzyme activity, amino acids transport, and peptide metabolism at the brush border membrane of enterocytes in the intestinal epithelium (Fig. S1, Table S1). TMPRSS2 was found enhanced in GIT and exocrine glands of pancreas (Fig. S2, Table S2) and found co-localized with ACE2 in enterocytes (Fig. S3).

Discussion

We found enriched transcriptomic and proteomic expression of SARS-CoV-2 binding receptor ACE2 in lower GIT (small intestine, colon, and rectum) and GB (Fig. 1-3. Table 1). The digestive system specific functional enrichment map of the ACE2 gene suggests its role in regulating secretory/absorptive functions at the brush border membrane of the enterocytes in the intestinal lining epithelium (Fig.S1, Table S1). The co-localized expression of SARS-CoV-2 cell entry associated protease TMPRSS2 in the enterocytes make these cells potential sites for viral infection (Fig. S2-3, Table S2).

ACE2 is a homologue of angiotensin-I converting enzyme (ACE), the key enzyme of the renin-angiotensin system (RAS). It is an integral membrane protein and localizes predominantly at the apical surface of polarized epithelial cells where it is proteolytically cleaved within its ectodomain to release a soluble form (21,22). Currently, SARS-CoV-2 mediated binding of ACE2 and the following downstream events leading to tissue damage are little known. Presumptive understanding of SARS-CoV-2 driven pathology is being borrowed from SARS-CoV-1 which was the etiological basis of SARS pandemic in 2003. Uniquely, it acted on the same receptor as SARS-CoV-2 and led to many clinical manifestations similar to COVID-19 (23). Studies utilizing cell lines to decipher SARS pathology in lung tissue showed that the spike protein of SARS-CoV-1 (SARS-S) induced TNFα production which facilitated virus entry (24). TNFα also led to inflammation of the cell membrane and consequently tissue damage (22-24). SARS-CoV-1 was also showed to cause downregulation of ACE2 expression at the cell membrane level (22,25). Existing literature regarding expression of ACE2 in human tissues are rare. Hamming et al, studied ACE2

protein expression in human tissues in reference to SARS-CoV-1 (26). Our findings for ACE2 protein expression in digestive system components are in line with the findings of their study (26). Recently, enriched expressions of ACE2 (and TMPRSS2) in enterocytes and mucus producing cells were shown using single cell m-RNA expression studies (27,28). Enriched expression of SARS-CoV-2 binding receptor ACE2 in the mucosal glands and enterocytes (including brush border cells) in the lining epithelium (Fig. 2e-h, Table 1) of the lower GIT indicates that GI cells are potential sites for virus replication. Evidence of the viral shedding in the feces shown in some studies indicates possible replication of the virus inside the GI cells which, in turn may explain GI manifestations of COVID-19 in addition to disease recurrence (29,30). Recent *in situ* studies using recombinant strain of SARS-CoV-2 showed that the virus can potentially infect and replicate in human intestinal tissue (31,32). Further, GIT to pulmonary spread of SARS-CoV-2 infection has been indicated by a study by Sun *et al* who showed in a transgenic mouse expressing human ACE2 that a direct intragastric inoculation of SARS-CoV-2 can cause productive infection and lead to pulmonary pathological changes (33).

How the virus reaches the GI is arguable? Some authors speculated a fecal-oral route of entry (8). Shedding of infectious SARS-CoV-2 in feces was also detected in occasional COVID-19 patients (12,13). We examined possibility of this route of entry based on the expression pattern of ACE2 along the length of the GIT (Fig. 1, 2, Table 1). Negligible or very low mRNA expression and undetectable proteomic expression of ACE2 in the mouth cavity (including tongue, oral mucosa, and salivary glands), esophagus, and stomach (Fig. 1, 2a-d, Table 1) indicate these parts of GIT can be resistant for the virus entry. But this observation does not negate a possible site of virus entry through the ACE2 receptors present in the lower GIT in case of fecal-oral transmission. It is then intriguing that how SARS-CoV-2 survives extremes of pH within the digestive system milieu (gastric-1.5 to 3.5, pancreatic-7.5, bile acid-7-8) while passing along the length of GIT. Recently, Chin *et al.,* 2020 showed *in vitro* that SARS-CoV-2 can survive at wide range of pH values at room temperature (pH3-10) (34). This can be further explained by an earlier study by Hirose et al, who, in an experimental, model demonstrated that RNA viruses like influenza A and B (when swallowed) can survive extremes of pH and maintain infectivity with help of the mucus cover lining GIT allowing their safe passage and even excretion in feces (35). Mucus cells are abundant all along the length of the GIT which can contribute to the carriage and survival of SARS-CoV-2 thereby contributing to the so hypothesized fecal-oral transmission. This also hints that shedding of the virus in feces always may not be indicative of its replication in GI cells; all those patients who shed virus in stools don't necessarily present with digestive symptoms (29).

Healthy intestinal mucosa may not be well conducive for the entry of the virus due to the presence of unique multi-layer barrier system, though a prior inflammatory condition which disrupts mucosal barrier may render the lower GI entry of the SARS-CoV-2 using ACE2 receptor and its replication inside tissue plausible (36). Inflammatory conditions in GIT enhance the expression of ACE2 in the luminal epithelium which can provide additional support for the entry of the virus (37). Once inside the GI cells, the virus can replicate there and may orchestrate viral toxin mediated cell injury ensuing further inflammation, thereby, giving rise to gastroenteritis like symptoms (diarrhea, nausea, and vomiting, abdominal pain) (22,24,38). Other than the fecal-oral route, an alternative route of viral entry to the GI cells may be through the tissue microvasculature. Though this may not be highly probable but this premise does warrant consideration. In that case, fecal viral shedding can happen after sloughing of the inflamed/necrosed intestinal mucosa. Currently, data is limited which

support presence of SARS-CoV-2 in the blood, however such evidence is available for other coronaviruses infections like SARS and MERS (29,39-41).

ACE2 is known to regulate sodium-dependent amino acid and glucose transporters in the enterocytes brush border which physiologically engage in the absorption of nutrients from the digested food, and maintain osmotic and electrolyte balance across the GI lining epithelium (11,14). In a recent study Yan et al., 2020 showed that SARS-CoV-2 can bind to the complex of ACE2 with B0AT1(Slc6a19)—a major sodium dependent neutral amino acid transporter present in the epithelial lining of human intestine (and also in kidneys) (1,42). The dysregulation of the intestinal ion transporters has been implicated in the pathophysiology of infectious diarrhea and malabsorption disorders (15,16). Literature also suggests that a dysregulation of these transporters can ensue interleukin/cytokine mediated intestinal inflammation and can give rise to digestive symptoms (14). An enhanced GI expression of ACE2 is known in inflammatory bowel diseases (IBDs) which present with similar symptoms as in COVID-19 patients (14,43).

Based on the findings of this study and supportive evidence from the literature, we propose that a virus binding-ACE2 mediated dysregulation of the sodium dependent nutrient transporters may be a plausible basis for the digestive symptoms in COVID-19. Prior intestinal inflammatory conditions like IBD may raise the susceptibility of SARS-CoV-2 infection through fecal-oral transmission. ACE2 mediated dysregulation of SGLT1 and/or SLC5A1 at intestinal epithelium also links it to the pathogenesis of diabetes mellitus (18,19). The SGLT1 transporters are physiologically involved in active absorption of glucose across the intestinal epithelium and its virus binding receptor ACE2 mediated dysregulation may exacerbate the existing impaired glycemic control in COVID-19 patients with diabetes mellitus (19). (Sufficient data on glycemic control in COVID-19 patients is lacking for now, impaired glycemic control was stated as an independent risk factor predicting morbidity and mortality in SARS patients with diabetes mellitus (44).) ACE2 mediated downregulation of SGLT1 in intestinal epithelium prevents hyperglycemia in rat models of the diabetes mellitus (45,46). Though direct evidence is lacking in terms of the effect of SARS-CoV-2 binding on ACE2 on its signaling cascades, however, substantiation from SARS-CoV-1 studies (for SARS) suggests that it can downregulate ACE2 expression (25). Such an eventuality can lead to upregulation of SGLT1 thereby precipitating hyperglycemia (45,46). (SGLT1 inhibitors are being used in treatment of diabetes mellitus, their use in COVID-19 patients may need a rethinking for the dose adjustments (47).)

Our data showed undetectable expression of ACE2 and TMPRSS2 proteins in insulin producing Islets of Langerhans of the pancreas raising an insulin independent possibility of dysregulated intestinal SGLT1 transporters. This bolsters the rationale behind diabetes related increased morbidity/mortality in COVID-19 patients. Apart from intestine SGLT1 is known to be widely expressed in other human tissues like proximal tubule of kidney, heart, and liver (proteinatlas.org/ENSG00000100170-SLC5A1/tissue) where it regulates the glucose absorption. An ACE2-mediated dysregulation of SGLT1 in COVID-19 patients warrants further investigation.

High expression of ACE2 in glandular cells of the GB indicates that this also can be a potential site for the virus replication. (Contrastingly, we found low m-RNA and undetectable proteomic expression of TMPRSS2 in glandular cells of GB, however, robust expression of another serine protease CTSL is noted in these cells in the records of Human Protein Atlas (48), which may be able to substitute for TMPRSS2 (1)) GB has a luminal connection to the duodenum through cystic and common bile duct (CBD). Though this connection is guarded

by a sphincter (of Oddi) present in duodenal mucosa, it doesn't create an anatomical barrier and, therefore, a viral invasion along the mucosal epithelium remains a possibility.

GB is the physiological storage site for the bile secreted from the hepatocytes, and pathology of this organ can also contribute to the digestive symptoms present in COVID-19 patients. GB has been a known reservoir for *Salmonella typhi*, a bacterium causing enteric fever, and one of the cited reasons for disease recurrence (49). The thick mucin secreted from its glandular cells can provide a protective environment for survival of SARS-CoV-2 (as we discussed above for GI lining epithelium) (35). Hence, GB homing may act as a mechanism for the replication of the virus even without ensuing a local tissue injury.

Continued replication of the SARS-CoV-2 in the intestinal tissue, and possibly in GB, may be a potential reason for the recurrence of SARS-CoV-2 in the light of the diagnostic tests as has been noted in some COVID-19 patients after being discharged from the hospital (40,50). A post-mortem study of these organs in COVID-19 patients may provide some confirmation in this regard.

Based on the observed pattern of tissue specific expression of ACE2 (which binds to SARS-CoV-2) in the components of the digestive system in normal individuals, we propose that an ACE2 based mechanism may be involved in the pathogenesis of digestive symptoms, increased diabetes-associated mortality risk, and disease recurrence in COVID-19.

Limitations

All the aspects of the plausible SARS-CoV-2 binding receptor ACE2 mediated pathology in the digestive system which we have discussed above are based on the distribution of the virus cell entry related factors in the normal tissue. Hence, this study presents indirect evidence which needs to be validated in actual patients before reaching any conclusion.

Future directions

Further studies are advisable to understand the molecular mechanisms involved in the SARS-CoV-2 binding receptor ACE2 mediated dysregulation of the intestinal nutrient transporters and finding out COVID-19 specific drug targets. Inter-individual variations in frequency of the digestive symptoms, diabetes associated mortality, and recurrences may depend upon the genotype specific variations in ACE2 expression and other patient specific characteristics (like age, sex, and comorbidity). A study of these variables in the disease pathogenesis may help in deciding personalized therapeutic management for the COVID-19 cases.

Conflict of Interest

All the authors declare "No Conflict of Interest".

Author Contributions

AK conceived the idea. AK wrote the first draft. MAF, VP, KR, MK, CK, KK, PK, PP, HN, RKN, SNP, RQ, and SK revised the draft. RKN, KR, PP, PK, and VP contributed to data analysis, and prepared tables and figures.

Funding

There was no dedicated funding for this project.

Data Availability

Data used for this study can be accessed at the following link: https://www.proteinatlas.org/about/download

Acknowledgments

The authors acknowledge The Human Protein Atlas (https://www.proteinatlas.org/) for ready availability of data in the public domain. This manuscript has been released as a pre-print at BioRxiv [bioRxiv 2020.04.14.040204, Kumar A, et al. (51)].

References

1. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020;367(6485). doi:10.1126/science.abb2762
2. Shang J, Ye G, Shi K. et al. Structural basis of receptor recognition by SARS-CoV-2. 2020. Nature. https://doi.org/10.1038/ s41586-020-2179-y.
3. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020. pii:S0092-8674(20)30262-2. doi: 10.1016/j.cell.2020.02.058
4. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell (2020) **181**:271-280.e8. doi:10.1016/j.cell.2020.02.052
5. Guan WJ, Ni ZY, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. doi: 10.1056/NEJMoa2002032
6. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, Li P, Hu B, Wang J, Hu C, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China. Am J Gastroenterol (2020) **115**:1. doi:10.14309/ajg.0000000000000620
7. Pan L, Mu M, Ren HG, Yang P, Sun Y, Wang R. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020. 20. doi:10.14309/ajg.0000000000000620
8. Hindson J. COVID-19: faecal–oral transmission? Nat Rev Gastroenterol Hepatol 2020. 1-1. doi: 10.1038/s41575-020-0295-7
9. Minodier L, Charrel RN, Ceccaldi PE et al. Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: what do we know?. Virol J 2015;12(1): 215. doi: 10.1186/s12985-015-0448-4
10. Leung WK, To KF, Chan PK et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterol 2003;125(4):1011-1017. DOI: 10.1016/s0016-5085(03)01215-0
11. Broer S & Fairweather SJ. Amino acid transport across the mammalian intestine. Compr Physiol 2011;9(1):343-373. doi: 10.1002/cphy.c170041

12. Zhang Y, Chen C, Zhu S, Shu C, Wang D, Song J, Song Y, Zhen W, Feng Z, Wu G, et al. Isolation of 2019-nCoV from a Stool Specimen of a Laboratory-Confirmed Case of the Coronavirus Disease 2019 (COVID-19). China CDC Weekly, 2020, Vol 2, Issue 8, Pages 123-124 (2020) **2**:123–124. doi:10.46234/CCDCW2020.033

13. Xiao F, Sun J, Xu Y, Li F, Huang X, Li H, Zhao J, Huang J, Zhao J. Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. Emerg Infect Dis (2020) **26**: doi:10.3201/eid2608.200681

14. Hashimoto T, Perlot T, Rehman A et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 2012;487(7408):477-481. doi: 10.1038/nature11228

15. Das S, Jayaratne R, Barrett KE. The role of ion transporters in the pathophysiology of infectious diarrhea. Cell Mol Gastroenterol Hepatol 2018;6(1):33-45. doi: 10.1016/j.jcmgh.2018.02.009

16. Milne MD. Disorders of intestinal amino-acid transport. J Clin Pathol Suppl (R Coll Pathol) 1971; 5: 41–44.

17. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med 2020;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8

18. Bindom SM & Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol 2009;302(2):193-202. doi: 10.1016/j.mce.2008.09.020

19. Navale AM & Paranjape AN. Glucose transporters: physiological and pathological roles. Biophys Rev 2016;8(1):5-9. doi: 10.1007/s12551-015-0186-2

20. Wu Y, Guo C, Tang L et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020;5(5):434-435. doi: 10.1016/S2468-1253(20)30083-2.

21. Ren X, Glende J, Al-Falah M et al. Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus. J Gen Virol 2006; 87(6):1691-1695. DOI: 10.1099/vir.0.81749-0

22. Jia HP, Look DC, Tan P et al. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol 2009;297(1):L84-L96. doi: 10.1152/ajplung.00071.2009

23. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related?. Clin Microbiol Infect 2020. pii: S1198-743X(20)30171-3. doi: 10.1016/j.cmi.2020.03.026

24. Haga S, Yamamoto N, Nakai-Murakami C et al. Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry. Proc Natl Acad Sci USA 2008;105(22):7809-7814. doi: 10.1073/pnas.0711241105

25. Kuba K, Imai Y, Rao S et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med 2005;11(8); 875-879. DOI: 10.1038/nm1267

26. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203(2): 631-637. DOI: 10.1002/path.1570

27. Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, Talavera-López C, Maatz H, Reichart D, Sampaziotis F, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med (2020)1–7. doi:10.1038/s41591-020-0868-6

28. Muus C, Luecken MD, Eraslan G, Waghray A, Heimberg G, Sikkema L, Kobayashi Y, Vaishnav ED, Subramanian A, Smilie C, et al. Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. bioRxiv (2020)2020.04.19.049254. doi:10.1101/2020.04.19.049254

29. Young BE, Ong SWX, Kalimuddin S et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA 2020. doi:10.1001/jama.2020.3204

30. Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology 2020. pii: S0016-5085(20)30281-X. doi: 10.1053/j.gastro.2020.02.054

31. Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, Ravelli RBG, Paul van Schayck J, Mykytyn AZ, Duimel HQ, et al. SARS-CoV-2 productively infects human gut enterocytes. Science (80-) (2020)eabc1669. doi:10.1126/science.abc1669

32. Zhou J, Li C, Liu X, Chiu MC, Zhao X, Wang D, Wei Y, Lee A, Zhang AJ, Chu H, et al. Infection of bat and human intestinal organoids by SARS-CoV-2. Nat Med (2020)1–7. doi:10.1038/s41591-020-0912-6

33. Sun S-H, Chen Q, Gu H-J, Yang G, Wang Y-X, Huang X-Y, Liu S-S, Zhang N-N, Li X-F, Xiong R, et al. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. Cell Host Microbe (2020) doi:10.1016/j.chom.2020.05.020

34. Chin A, Chu J, Perera M et al. Stability of SARS-CoV-2 in different environmental conditions. The Lancet Microbe 2020;0(0). DOI:https://doi.org/10.1016/S2666-5247(20)30003-3

35. Hirose R, Nakaya T, Naito Y et al. Mechanism of human influenza virus RNA persistence and virion survival in feces: mucus protects virions from acid and digestive juices. J Infect Dis 2017; 216(1): 105-109. doi: 10.1093/infdis/jix224

36. Okumura R & Takeda K. Maintenance of intestinal homeostasis by mucosal barriers. Inflamm Regen. 2018; 38(1): 5.

37. Khajah MA, Fateel MM, Ananthalakshmi KV, Luqmani YA. Anti-inflammatory action of angiotensin 1-7 in experimental colitis. PLoS One. 2016;11(3):1-24. doi: 10.1016/j.dci.2017.05.005

38. Gu J & Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol 2007; 170(4):1136-1147. DOI: 10.2353/ajpath.2007.061088

39. Chang L, Yan Y & Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020. pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.003

40. Chen D, Xu W, Lei Z et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report. Int J Infect Dis 2020; 93:297-299. doi: 10.1016/j.ijid.2020.03.003

41. Kim SY, Park SJ, Cho SY et al. Viral RNA in blood as indicator of severe outcome in Middle East respiratory syndrome coronavirus infection. Emerg Infect Dis 2016;22(10): 1813. doi: 10.3201/eid2210.160218

42. Singer D & Camargo SM. Collectrin and ACE2 in renal and intestinal amino acid transport. Channels 2011;5(5): 410-423. doi: 10.4161/chan.5.5.16470

43. Sueyoshi R, Ignatoski KMW, Daignault S, Okawada M, Teitelbaum DH. Angiotensin converting enzyme-inhibitor reduces colitis severity in an IL-10 knockout model. Dig Dis Sci 2013;58(11): 3165-3177. doi: 10.1007/s10620-013-2825-4

44. Yang JK, Feng Y, Yuan MY et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006;23(6): 623-628. DOI: 10.1111/j.1464-5491.2006.01861.x

45. Wong TP, Ho KY, Ng EK, Debnam ES, Leung PS. Upregulation of ACE2-ANG-(1–7)-Mas axis in jejunal enterocytes of type 1 diabetic rats: implications for glucose transport. Am J Physiol Endocrinol Metab 2012; 303(5): E669-E681. doi: 10.1152/ajpendo.00562.2011

46. Chan LKY & Leung PS. Multifaceted interplay among mediators and regulators of intestinal glucose absorption: potential impacts on diabetes research and treatment. Am J Physiol Endocrinol Metab 2015; 309(11): E887-E899. doi: 10.1152/ajpendo.00373.2015

47. Tahrani AA, Barnett AH & Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013;1(2):140-151. doi: 10.1016/S2213-8587(13)70050-0

48. SARS-CoV-2 related proteins - The Human Protein Atlas. Available at: https://www.proteinatlas.org/humanproteome/sars-cov-2 [Accessed June 1, 2020]

49. Gonzalez-Escobedo G, Marshall JM & Gunn JS. Chronic and acute infection of the gall bladder by Salmonella Typhi: understanding the carrier state. Nat Rev Microbiol 2011;9(1):9-14. doi: 10.1038/nrmicro2490

50. Zhou L, Liu K & Liu HG. Cause analysis and treatment strategies of" recurrence" with novel coronavirus pneumonia (COVID-19) patients after discharge from hospital. (Chinese journal of tuberculosis and respiratory diseases (Beijing)) 2020;43: E028. doi: 10.3760/cma.j.cn112147-20200229-00219

51. Kumar A, Faiq MA, Pareek V, Raza K, Narayan RK, Prasoon P, Kumar P, Kulandhasamy M, Kumari C, Kant K, Singh HN. Relevance of enriched expression of SARS-CoV-2 binding receptor ACE2 in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients. bioRxiv. 2020 Jan 1. doi: https://doi.org/10.1101/2020.04.14.040204

529

Figures and Tables



Figure 1 Physiological expression of SARS-CoV-2 binding receptor ACE2 in human digestive system a. mRNA b. Protein. Data Source: The Human Protein Atlas.



Figure 2 Immunohistochemical expression of ACE2 protein in human gastrointestinal tract a. Oral mucosa b. Salivary gland c. Esophagus d. Stomach e. Duodenum f. Small intestine g. Colon h. Rectum. Orange arrow heads show antibody stained cells. Data Source: The Human Protein Atlas. **Abbreviations:** GC- goblet cells, Bv - Blood vessels, LP - Lamina propria, SMC - Smooth muscle cells.



Figure 3 Immunohistochemical expression of ACE2 protein in Human tissue a. Pancreas b. Liver c. Gall bladder. Orange arrow heads show antibody stained cells. (In pancreatic tissue blood vessels (Bv) but not in the exocrine or endocrine glandular cells can be seen expressing ACE2.) Data Source: The Human Protein Atlas. **Abbreviations:** Bv - Blood vessels, LP - Lamina propria, SMC - Smooth muscle cells.



Figure S1 ACE2 gene enrichment map for Digestive system functions.



549

550 **Figure S2 Physiological expression of SARS-CoV-2 cell entry associated protease TMPRSS2 in**

551 **human digestive system a. mRNA b. Protein.** Data Source: The Human Protein Atlas.



552

553

554 **Figure S3 Immunohistochemical expression of TMPRSS2 protein in Small Intestine of human**

555 **gastrointestinal tract Orange arrow heads show antibody stained cells.** Data Source: The Human

556 Protein Atlas. **Abbreviations:** GC- goblet cells, LP - Lamina propria.

557

558

559 Table 1 Physiological expression (mRNA and protein) of SARS-CoV-2 binding receptor
560 ACE2 in human digestive system.

Tissue	**Cellular components**	**RNA Expression (NX)**	**Protein Expression**
Tongue	Squamous epithelial cells	0.5	Not detected
Oral mucosa	Squamous epithelial cells	0	Not detected
Salivary gland	Glandular cells	1.1	Not detected
Esophagus	Squamous epithelial cells	1.2	Not detected
Stomach	Glandular cells	0.5	Not detected
Small Intestine (Duodenum)	Glandular cells	46.0	High
Small Intestine (Jejunum&Ileum)	Glandular cells	122.0	High
Appendix	Glandular cells	0.8	Not detected
	Lymphoid tissue		Not detected
Colon	Endothelial cells	49.1	Not detected
	Glandular cells		Low
	Peripheral nerve/ganglion		Not detected
Rectum	Glandular cells	1.3	Low
Liver	Bile duct cells	1.2	Not detected
	Hepatocytes		Not detected
Gall bladder	Glandular cells	16.4	High
Pancreas	Exocrine glandular cells	1.6	Not detected
	Islets of Langerhans		Not detected

561

562

563

564

565

566 **Table S1 ACE2 gene enrichment for Digestive system functions.**

GO. ID	Description	P Value	FDR	Phenotype	Gene
GO:0008241	Peptidyl-dipeptidase activity	0.00397219	0.00397219	1	ACE2
GO:0008239	Dipeptidyl-peptidase activity	0.01853691	0.01853691	1	ACE2
GO:0004181	Metallocarboxypeptidase activity	0.03707382	0.03707382	1	ACE2
GO:0004180	Carboxypeptidase activity	0.06090698	0.06090698	1	ACE2
GO:0004177	Aminopeptidase activity	0.06487918	0.06487918	1	ACE2
GO:0008235	Metalloexopeptidase activity	0.07944389	0.07944389	1	ACE2
GO:0140272	Exogenous protein binding	0.10062893	0.10062893	1	ACE2
GO:0008238	Exopeptidase activity	0.1509434	0.1509434	1	ACE2
GO:0008237	Metallopeptidase activity	0.23965574	0.23965574	1	ACE2
GO:0004175	Endopeptidase activity	0.58126448	0.58126448	1	ACE2
GO:0070011	Peptidase activity, acting on L-amino acid peptides	0.8142999	0.8142999	1	ACE2
GO:0008233	Peptidase activity	0.84872559	0.84872559	1	ACE2
GO:0005515	Protein binding	1	1	1	ACE2
GO:0140096	Catalytic activity, acting on a protein	1	1	1	ACE2
GO:0015827	Tryptophan transport	0.03708254	0.03708254	1	ACE2
GO:0051957	Positive regulation of amino acid transport	0.17614208	0.17614208	1	ACE2
GO:0032800	Receptor biosynthetic process	0.24103652	0.24103652	1	ACE2
GO:0003081	Regulation of systemic arterial blood pressure by renin-angiotensin	0.2595778	0.2595778	1	ACE2
GO:0051955	Regulation of amino acid transport	0.30593097	0.30593097	1	ACE2
GO:0016486	Peptide hormone processing	0.32447224	0.32447224	1	ACE2
GO:1901890	Positive regulation of cell junction assembly	0.33374288	0.33374288	1	ACE2
GO:0032892	Positive regulation of organic acid transport	0.33374288	0.33374288	1	ACE2

GO:0051954	Positive regulation of amine transport	0.34301352	0.34301352	1	ACE2
GO:1903793	Positive regulation of anion transport	0.49134368	0.49134368	1	ACE2
GO:0051952	Regulation of amine transport	0.87143974	0.87143974	1	ACE2
GO:0044070	Regulation of anion transport	0.91779292	0.91779292	1	ACE2
GO:0019538	Protein metabolic process	1	1	1	ACE2
GO:0019222	Regulation of metabolic process	1	1	1	ACE2
GO:0015849	Organic acid transport	1	1	1	ACE2
GO:0015711	Organic anion transport	1	1	1	ACE2
GO:0010817	Regulation of hormone levels	1	1	1	ACE2
GO:0009893	Positive regulation of metabolic process	1	1	1	ACE2
GO:0016485	Protein processing	1	1	1	ACE2
GO:0032879	Regulation of localization	1	1	1	ACE2
GO:0046942	Carboxylic acid transport	1	1	1	ACE2
GO:0043270	Positive regulation of ion transport	1	1	1	ACE2
GO:0043269	Regulation of ion transport	1	1	1	ACE2
GO:0043170	Macromolecule metabolic process	1	1	1	ACE2
GO:0043112	Receptor metabolic process	1	1	1	ACE2
GO:0042445	Hormone metabolic process	1	1	1	ACE2
GO:0008152	Metabolic process	1	1	1	ACE2
GO:0001816	Cytokine production	1	1	1	ACE2
GO:0001817	Regulation of cytokine production	1	1	1	ACE2
GO:0006820	Anion transport	1	1	1	ACE2
GO:0006812	Cation transport	1	1	1	ACE2
GO:0006811	Ion transport	1	1	1	ACE2
GO:0006807	Nitrogen compound metabolic process	1	1	1	ACE2
GO:0006518	Peptide metabolic process	1	1	1	ACE2

GO:0006508	Proteolysis	1	1	1	ACE2
GO:0071705	Nitrogen compound transport	1	1	1	ACE2
GO:0071704	Organic substance metabolic process	1	1	1	ACE2
GO:0071702	Organic substance transport	1	1	1	ACE2
GO:0051604	Protein maturation	1	1	1	ACE2
GO:0051050	Positive regulation of transport	1	1	1	ACE2
GO:0051049	Regulation of transport	1	1	1	ACE2
GO:0031526	Brush border membrane	0.08612643	0.08612643	1	ACE2
GO:0005903	Brush border	0.16610098	0.16610098	1	ACE2
REAC:R-HSA-2980736	Peptide hormone metabolism	0.03360393	0.03360393	1	ACE2
REAC:R-HSA-392499	Metabolism of proteins	0.760808	0.760808	1	ACE2

584 **Table S2 Physiological expression (mRNA and protein) of SARS-CoV-2 cell entry**
585 **associated protease TMPRSS2 in human digestive system.**

586

Tissue	Cellular components	RNA Expression (NX)	Protein Expression
Tongue	Squamous epithelial cells	3.9	Not detected
Oral mucosa	Squamous epithelial cells	0	Not detected
Salivary gland	Glandular cells	52.3	Low
Esophagus	Squamous epithelial cells	10.7	Not detected
Stomach	Glandular cells	36.7	Medium
Small Intestine (Duodenum)	Glandular cells	17.5	Low
Small Intestine (Jejunum & Ileum)	Glandular cells	75.6	Low
Appendix	Glandular cells	15.5	Low
	Lymphoid Tissue		Not detected
Colon	Endothelia cells	38.7	Not detected
	Glandular cells		Not detected
Rectum	Glandular cells	18.5	Low
Liver	Bile duct cells	18.4	Not detected
	Hepatocytes		Not detected
Gall bladder	Glandular cells	17.3	Not detected
Pancreas	Exocrine glandular cells	64.5	Medium
	Islets of Langerhans		Not detected

587


RNA Expression
Pancreas
1.6
Gall Bladder
16.4
Liver
1.2
Rectum
1.3
Colon
49.1
Appendix
0.8
Small Intestine (Jejunum &...
122
Small Intestine (Duodenum)
46
Stomach
0.5
Oesophagus
1.2
Salivary Gland
1.1
Oral Mucosa
0
Tongue
0.5
0
20
40
60
80
100
120
140
CONSENSUS NORMALIZED EXPRESSION (NX)
a


Protein Expression
Pancreas
Gall Bladder
Liver
Rectum
Colon
Appendix
Small Intestine (Jejunum & Ileum)
Small Intestine (Duodenum)
Stomach
Oesophagus
Salivary Gland
Oral Mucosa
Tongue
ND
LOW
MEDIUM
HIGH
Protein Expression Score
b


Oral mucosa
Bv
Stratified Squamous Epithelium
Bv
50 µm
a


Salivary gland
LP
Duct
Bv
Glandular cells
Bv
50 µm
b


Esophagus
Stratified Squamous Epithelium
LP
50 µm
c


Stomach
Glandular cells
50 µm
d


Small Intestine
(Duodenum)
GC
GC
GC
GC
Glandular cells
SMC
50 µm
e


Small Intestine
(Jejunum)
GC
LP
GC
Glandular cells
LP
LP
LP
50 µm
f


Colon
Endothelial cells
Glandular cells
Muscularis mucosa (SMC)
Peripheral nerve
LP
50 µm
g


Rectum
Rectum
LP
GC
GC
Glandular Cells
LP
GC
SMC
50 µm
h


a
Exocrine Glandular cells
By
Islets of
Langerhans
50 µm
Pancreas
b
Hepatocytes
Bile duct cells
50 µm
Liver
c
LP
LP
Exocrine Glandular cells
LP
50 µm
Gall Bladder


metallocarboxypeptidase activity
metalloexopeptidase activity
aminopeptidase activity
tryptophan transport
peptidyl-dipeptidase activity
dipeptidyl-peptidase activity
carboxypeptidase activity
Peptide hormone metabolism
brush border membrane


RNA Expression
Pancreas
64.5
Gall bladder
17.3
Liver
18.4
Rectum
18.5
Colon
38.7
Appendix
15.5
Small Intestine (Jejunum&Ileum)
75.6
Small Intestine (Duodenum)
17.5
Stomach
36.7
Esophagus
10.7
Salivary gland
52.3
Oral mucosa
0
Tongue
3.9
0 10 20 30 40 50 60 70 80
a
CONSENSUS NORMALIZED EXPRESSION (NX)


Protein Expression
Pancreas
Gall bladder
Liver
Rectum
Colon
Appendix
Small Intestine (Jejunum&Ileum)
Small Intestine (Duodenum)
Stomach
Esophagus
Salivary gland
Oral mucosa
Tongue
ND
LOW
MEDIUM
HIGH
b
PROTEIN EXPRESSION SCORE


Small Intestine
(Jejunum)
LP
GC
Glandular cells
GC
GC
LP
GC
LP
50 µm

Physiological Condition



Maintain the fluid and electrolyte homeostasis

Pathological Condition (SARS-CoV-2 infection)